# Clarus Ventures: portfolio, investments and team > Clarus Ventures is a vc firm based in United States. 73 investments on record, 4 in the last 12 months, latest Oct 2026. Source: https://millionrounds.com/fund/blackstone (Millionrounds; every figure on the page links to its filing or article) United States · [Investor](https://millionrounds.com/investors) # Clarus Ventures Last cheque observed Oct 2026; 73 cheques on record. Email Deploying now New fund $209M, Oct 2026 VC firm Growth Pre-seed Seed AI & Machine Learning Broadcasting Community Follow Clarus Ventures and see its new cheques in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Ffund%2Fblackstone) Deploying now **100%** of best year **4** **cheques in 12 months**, 73 on record Since the last cheque **23** days **00** hrs **00** min **00** sec Median round **$350M** Rounds led **3 of 73** Sole investor **6 rounds** Exits **10 from the portfolio** Mostly in **United States, 85%** Pitch Clarus Ventures Another investor of this name exists, and we could not establish from the rounds which of them the press meant. Treat the record below as possibly belonging to either. [Tell us which](https://millionrounds.com/corrections?slug=blackstone) if you know. ## Clarus Ventures highlights - 01 4 cheques in the last 12 months - 02 Mostly Series B and Series A: 49% of its rounds - 03 Sole investor in 6 rounds, median $18M - 04 10 exits from the portfolio ## What they do > Filed 2 private fund offerings with the SEC, the most recent in 2025-10 From their own website - **Type:** VC firm (from a list, unverified) - **Cheque size:** Not stated - **Stages:** Growth Pre-seed Seed Series A Series B - **Sectors:** AI & Machine Learning Broadcasting Community - **Based in:** Cambridge, United States - **Cold pitches:** Not stated ## The record Every round we can evidence, newest first **73 appearances** - **2026** 4 rounds - **Oct** **[Waymo](https://millionrounds.com/company/waymo)** Debt · US · Firms' own news pages **$5.0B** *Led* - **Oct** **[Lambda](https://millionrounds.com/company/lambda)** Growth · US · Leap Ventures **$4.0B** *Led* - **Jul** **[Shield AI](https://millionrounds.com/company/shield-ai)** Series G · US · InnovationX **$1.5B** With 8 others - **May** **[Neysa](https://millionrounds.com/company/neysa)** Growth · IN · NTTVC **$1.2B** *Led* - **2021** 1 round - **Jul** **[Nature's Fynd](https://millionrounds.com/company/nature-s-fynd)** Series C · US · Firms' own news pages **$350M** With 6 others - **2019** 1 round - **Nov** **Pcysys** Series A · IL · FinSMEs **$10M** With 1 other - **2018** 1 round - **Jun** **[Preempt](https://millionrounds.com/company/preempt)** Series B · US · FinSMEs **$18M** With 3 others - **2017** 2 rounds - **Sept** **[Gritstone](https://millionrounds.com/company/gritstone)** Series B · US · FinSMEs **$93M** With 6 others - **Feb** **[IntSights](https://millionrounds.com/company/intsights)** Series B · IL · FinSMEs **$15M** With 4 others - **2016** 2 rounds - **Aug** **[JDA Software](https://millionrounds.com/company/jda-software)** US · Streetinsider **$570M** With 1 other - **Jun** **[Verodin](https://millionrounds.com/company/verodin)** Series A · US · Eweek **$10M** With 2 others - **2015** 1 round - **Oct** **[Gritstone oncology](https://millionrounds.com/company/gritstone-oncology)** Series A · US **$102M** With 6 others - **2014** 4 rounds - **Dec** **[Annexon](https://millionrounds.com/company/annexon)** Series A · US **$34M** With 2 others - **Nov** **[Flowonix](https://millionrounds.com/company/flowonix)** Debt · US **$20M** With 2 others - **Nov** **[Restoration Robotics](https://millionrounds.com/company/restoration-robotics)** Series C · US **$45M** With 3 others - **Oct** **[Imago BioSciences](https://millionrounds.com/company/imago-biosciences)** Series A · US **$27M** With 3 others - **2013** 8 rounds - **Nov** **[Catabasis Pharmaceuticals](https://millionrounds.com/company/catabasis-pharmaceuticals)** Series B · US · finsmes.com **$32M** With 4 others - **Jun** **[Heptares Therapeutics](https://millionrounds.com/company/heptares-therapeutics)** Series B · GB · finsmes.com **$21M** With 2 others - **May** **[NanoString Technologies](https://millionrounds.com/company/nanostring-technologies)** Venture · US · sec.gov **$150K** With 2 others - **Apr** **[SFJ Pharmaceuticals](https://millionrounds.com/company/sfj-pharmaceuticals)** Growth · US **$13M** Sole investor - **Apr** **[Pearl Therapeutics](https://millionrounds.com/company/pearl-therapeutics)** Growth · US **$42M** With 3 others - **Feb** **[Catabasis Pharmaceuticals](https://millionrounds.com/company/catabasis-pharmaceuticals)** Venture · US · fiercebiotech.com **$9.0M** With 3 others - **Jan** **[Avillion](https://millionrounds.com/company/avillion)** GB · finsmes.com **Undisclosed** With 1 other - **Jan** **[Cleave Biosciences](https://millionrounds.com/company/cleave-biosciences)** Growth · US **$15M** With 5 others - **2012** 8 rounds - **Dec** **[NanoString Technologies](https://millionrounds.com/company/nanostring-technologies)** Series E · US · reuters.com **$15M** With 6 others - **Nov** **[Pearl Therapeutics](https://millionrounds.com/company/pearl-therapeutics)** Series D · US · finsmes.com **$65M** With 3 others - **Oct** **[Pearl Therapeutics](https://millionrounds.com/company/pearl-therapeutics)** Growth · US **$23M** With 3 others - **Oct** **[SFJ Pharmaceuticals](https://millionrounds.com/company/sfj-pharmaceuticals)** Venture · US **$500K** Sole investor - **Jul** **[SFJ Pharmaceuticals](https://millionrounds.com/company/sfj-pharmaceuticals)** Growth · US **$21M** Sole investor - **Jun** **[Oxford Immunotec](https://millionrounds.com/company/oxford-immunotec)** Venture · GB · finsmes.com **$28M** With 8 others - **Apr** **[SFJ Pharmaceuticals](https://millionrounds.com/company/sfj-pharmaceuticals)** Growth · US **$35M** Sole investor - **Mar** **[Sientra](https://millionrounds.com/company/sientra)** Series C · US · fis.dowjones.com **$65M** With 2 others - **2011** 6 rounds - **Dec** **[Catabasis Pharmaceuticals](https://millionrounds.com/company/catabasis-pharmaceuticals)** Series A · US · catabasispharma.com **$8.0M** With 3 others - **Nov** **[NanoString Technologies](https://millionrounds.com/company/nanostring-technologies)** Series D · US · xconomy.com **$20M** With 5 others - **Oct** **[Cleave Biosciences](https://millionrounds.com/company/cleave-biosciences)** Series A · US · finsmes.com **$44M** With 5 others - **Aug** **[Restoration Robotics](https://millionrounds.com/company/restoration-robotics)** Series C · US · finsmes.com **$41M** With 3 others - **Jul** **[SARcode Bioscience](https://millionrounds.com/company/sarcode-bioscience)** Series B · US · finsmes.com **$44M** With 3 others - **Mar** **[Aerie Pharmaceuticals](https://millionrounds.com/company/aerie-pharmaceuticals)** Series B · US · sec.gov **$41M** With 4 others - **2010** 11 rounds - **Dec** **[TyRx Pharma](https://millionrounds.com/company/tyrx-pharma)** Venture · US · tyrx.com **$20M** With 2 others - **Sept** **[TetraLogic Pharmaceuticals](https://millionrounds.com/company/tetralogic-pharmaceuticals)** Series C · US · fis.dowjones.com **$5.0M** With 1 other An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor. ## The team Named by the firm itself, on a filing, its Form ADV or its company registration **24 named** AA **A.J. Agarwal** Senior Managing Director of the General Partner of the GP i Filing they signed AM **A.J. Murphy** Officer of the General Partner of the Special General Partner i Filing they signed AM **Agne Miller** DIRECTOR i Filing they signed AL **Alex Leonard** Director of the Manager i Filing they signed AN **Alicia Novak** Officer of the General Partner of the Special GP i Filing they signed AS **Allie Sweeney** Senior Managing Director of the General Partner of the GP i Filing they signed AZ **Amanda Ziegler** Managing Director of the General Partner of the GP i Filing they signed AG **Ana Gonzalez-Iglesias** Managing Director of the General Partner of the Special GP i Filing they signed AJ **Andre J. Fernandez** Director i Filing they signed AW **Anthony W. Beovich** Managing Director of the General Partner of the Special GP i Filing they signed AF **Anthony F. Marone, Jr** Managing Director of the General Partner of the GP i Filing they signed AF **Anthony F. Marone, Jr.** Managing Director of the General Partner of the Special GP i Filing they signed AP **Austin Pena** Managing Director of the General Partner of the Special GP i Filing they signed BF **Barbara Frank** Officer of the General Partner of the GP i Filing they signed BJ **Bennett J. Goodman** Executive Officer of Management Company i Filing they signed BE **Blackstone ETMA V (LUX) S.a r.l.** The General Partner i Filing they signed BJ **Brad J. Marshall** Executive Officer of the Investment Advisor i Filing they signed BN **Brett Newman** Senior Managing Director of the General Partner of the Special GP i Filing they signed BK **Brian Kim** Senior Managing Director of the General Partner of the Special GP i Filing they signed CC **Campbell Congdon** DIRECTOR i Filing they signed CP **Chris Placca** Officer of the General Partner of the Special GP i Filing they signed CS **Chris Striano** Senior Managing Director of the General Partner of the GP i Filing they signed CG **Christopher G. Striano** Senior Managing Director of the General Partner of the Special GP i Filing they signed CE **Christopher Ebanks** DIRECTOR i Filing they signed We also hold **178** people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them. ## Exits from the portfolio Companies it backed that were later bought or listed **10 in all** **[Heptares Therapeutics](https://millionrounds.com/company/heptares-therapeutics)** Bought by Sosei **Undisclosed** Feb 2015 **[TyRx Pharma](https://millionrounds.com/company/tyrx-pharma)** Bought by [Medtronic](https://millionrounds.com/fund/medtronic) **$160M** Jan 2014 **[Oxford Immunotec](https://millionrounds.com/company/oxford-immunotec)** Listed **$64M** Nov 2013 **[Aerie Pharmaceuticals](https://millionrounds.com/company/aerie-pharmaceuticals)** Listed **Undisclosed** Oct 2013 **[NanoString Technologies](https://millionrounds.com/company/nanostring-technologies)** Listed **$54M** Jun 2013 **[Pearl Therapeutics](https://millionrounds.com/company/pearl-therapeutics)** Bought by [AstraZeneca](https://millionrounds.com/fund/astrazeneca) **$1.1B** Jun 2013 **[SARcode Bioscience](https://millionrounds.com/company/sarcode-bioscience)** Bought by [Shire](https://millionrounds.com/fund/shire) **$160M** Mar 2013 **[Neomend](https://millionrounds.com/company/neomend)** Bought by C. R. Bard **$140M** Oct 2012 **[Taligen Therapeutics](https://millionrounds.com/company/taligen-therapeutics)** Bought by [Alexion Pharmaceuticals](https://millionrounds.com/fund/alexion-pharmaceuticals) **$111M** Jan 2011 **[Zogenix](https://millionrounds.com/company/zogenix)** Listed **Undisclosed** Nov 2010 An exit counts when it came after the firm's first round in the company. From historical deal records. New fund on file **$209M** raised in Oct 2026 From its SEC filing, not a journalist: a firm that has just raised has money to deploy. ## The cheque Growth Pre-seed Seed Median round joined **$350M** the round, not its cheque Alone, median **$18M** Led 3 of 73 rounds **4%** - **Sole investor:** 6 rounds - **Last cheque:** Oct 2026 - **Exits:** 10 from the portfolio Rounds by stage said on their site - Series B said *17* - Series A said *15* - Venture *10* - Series C *10* - Growth said *8* - Series D *5* - Pre-seed said *-* Cheques by month Led Joined Nov 2023 Oct 2026 Often in the room with - [5AM Ventures](https://millionrounds.com/fund/5am-ventures) 9 - [Alta Partners](https://millionrounds.com/fund/alta-partners) 8 - [New Leaf Venture Partners](https://millionrounds.com/fund/new-leaf-venture-partners) 8 - [SV Life Sciences](https://millionrounds.com/fund/sv-life-sciences) 7 - [Domain Associates](https://millionrounds.com/fund/domain-associates) 5 - [MedImmune Ventures](https://millionrounds.com/fund/medimmune-ventures) 5 **Pitching Clarus Ventures?** Put them on your fundraising board with this record on the card, and follow them to hear when they write a new cheque. Add to your CRM *→* ## Who they invest alongside The investors most often in the same rounds as Clarus Ventures. A count of rooms they were both in, not a relationship either has claimed. [**5AM Ventures** VC firm **9** rounds together](https://millionrounds.com/fund/5am-ventures)[**Alta Partners** VC firm **8** rounds together](https://millionrounds.com/fund/alta-partners)[**New Leaf Venture Partners** VC firm **8** rounds together](https://millionrounds.com/fund/new-leaf-venture-partners)[**SV Life Sciences** VC firm **7** rounds together](https://millionrounds.com/fund/sv-life-sciences)[**Domain Associates** VC firm **5** rounds together](https://millionrounds.com/fund/domain-associates)[**MedImmune Ventures** Corporate VC **5** rounds together](https://millionrounds.com/fund/medimmune-ventures)[**OrbiMed** Private equity **5** rounds together](https://millionrounds.com/fund/orbimed)[**Abingworth** VC firm **4** rounds together](https://millionrounds.com/fund/abingworth)[**Advanced Technology Ventures** VC firm **4** rounds together](https://millionrounds.com/fund/advanced-technology-ventures)[**DFJ** VC firm **4** rounds together](https://millionrounds.com/fund/dfj)[**HBM BioVentures** Growth equity **4** rounds together](https://millionrounds.com/fund/hbm-bioventures)[**Scale Venture Partners** VC firm **4** rounds together](https://millionrounds.com/fund/scale-venture-partners) ## Recently backed The latest companies Clarus Ventures put money into. [**Waymo** $5.0B · Oct 2026](https://millionrounds.com/company/waymo)[**Lambda** $4.0B · Oct 2026](https://millionrounds.com/company/lambda)[**Shield AI** $1.5B · Jul 2026](https://millionrounds.com/company/shield-ai)[**Neysa** $1.2B · May 2026](https://millionrounds.com/company/neysa)[**Nature's Fynd** $350M · Jul 2021](https://millionrounds.com/company/nature-s-fynd)[**Preempt** $18M · Jun 2018](https://millionrounds.com/company/preempt) ## Quick answers about Clarus Ventures ### What does Clarus Ventures invest in? Clarus Ventures invests most often at Series B and Series A (49% of the rounds on record), in sectors such as AI & Machine Learning, Broadcasting and Community. ### How active is Clarus Ventures? 73 investments on record, 4 of them in the last 12 months, and it led 3. The most recent was in Oct 2026. ### What has Clarus Ventures invested in recently? Its most recent investments on record: Waymo (Debt, Oct 2026), Lambda (Growth, Oct 2026) and Shield AI (Series G, Jul 2026). ### How big are Clarus Ventures's cheques? The median round it joins is $350M. ### Does Clarus Ventures lead rounds? Sometimes: it led 3 of its 73 investments on record (4%). ### Where does Clarus Ventures invest? Most of the companies it backs are in the United States (85%), the United Kingdom (8%) and Israel (5%). ### Is Clarus Ventures investing now? Yes: it is actively investing, with 4 investments in the last 12 months. ### Who does Clarus Ventures invest alongside? Most often 5AM Ventures (9 rounds together), Alta Partners (8 rounds together) and New Leaf Venture Partners (8 rounds together). ## Raising now? Find the investors who back rounds like yours, and keep every conversation on one fundraising board. Find similar investorsOpen your CRM Built from the rounds we watched, its filings and its own website, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections?slug=blackstone) · [Is this your firm? Claim it](https://millionrounds.com/claim?org=blackstone)